The Food and Drug Administration (FDA) has granted traditional approval to Calquence (acalabrutinib) with bendamustine and Rituxan (rituximab) for adults with previously untreated mantle cell lymphoma ...

A blockbuster AstraZeneca drug may now be used as an earlier treatment for mantle cell lymphoma (MCL), making ... for this rare and aggressive type of blood cancer. The FDA expanded approval ...

“With today’s approval, Calquence provides a critical new treatment option to mantle cell lymphoma patients in ... a backbone therapy across multiple blood cancers.” This approval also ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease progression or death by 27% in patients with previously ...

FDA Approves New Drug Combination for Mantle Cell LymphomaThe FDA has approved a new pill to treat adults with a type of blood cancer called mantle cell lymphoma (MCL).